Fortress Biotech
Open
$2.31
Prev. Close
$2.31
High
$2.31
Low
$2.30
Market Snapshot
$68.9M
-36.6
-2.79
$57.68M
101
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 101 full-time employees. The company went IPO on 2011-11-17. The firm has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
emptyResult
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 101 full-time employees. The company went IPO on 2011-11-17. The firm has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Recently from Cashu
Fortress Biotech Adapts to Geopolitical Shifts in the Evolving Biotech Landscape
Fortress Biotech Navigates a Changing Landscape Amid Evolving Geopolitical Strategies Fortress Biotech, a company focused on advancing innovative therapies, stands at a crucial juncture as geopolitica…
Fortress Biotech: Navigating Opportunities in the Evolving Energy Landscape and LNG Market
Fortress Biotech's Role in the Evolving Energy Landscape Fortress Biotech, a company traditionally known for its biopharmaceuticals, finds itself at a pivotal intersection within the broader energy se…
Fortress Biotech: Navigating New Energy Opportunities Amidst Healthcare Transformation
Fortress Biotech: A New Era of Opportunities in the Energy Sector Fortress Biotech, a company primarily focused on the development and commercialization of innovative therapeutics, finds itself at a c…
Fortress Biotech: Navigating Opportunities in the Evolving LNG Energy Sector
### Fortress Biotech: Advancing in the Evolving Energy Landscape Fortress Biotech is strategically positioned to leverage the significant developments in the liquefied natural gas (LNG) sector, partic…